1. Committee for Medicinal Products for Human Use (CHMP), EMA, Guideline on the limit of genotoxic impurities. London, UK (2006). .
2. Center for Drug Evaluation and Research (CDER), FDA, Genotoxic and Carcinogenic Impurities in Drug Substances and Products – Recommended Approaches, Silver Spring, MD, USA (2008). .
3. Analytical control of potentially genotoxic impurities in the pazopanib hydrochloride manufacturing process;Liu;J. Pharm. Biomed. Anal.,2009
4. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process;Giordani;Eur. J. Pharm. Sci.,2011
5. Recent advances in trace analysis of pharmaceutical genotoxic impurities;Liu;J. Pharm. Biomed. Anal.,2010